Drug intelligence / Profile preview

YCT2-2

Development stage: Preclinical
Modality: Small Molecules
Administration: Ophthalmic

Overview

YCT2-2 is an **arylpiperazine derivative** investigated for its ability to lower intraocular pressure (IOP), particularly in animal models of glaucoma and experimentally induced ocular hypertension. In studies conducted on rabbits, YCT2-2 administered as a topical ophthalmic solution resulted in a significant reduction of IOP both in normal recovery and alpha-chymotrypsin-induced glaucoma models. The compound demonstrates high solubility in acidic conditions, which may contribute to its efficacy as an IOP-lowering agent. Its precise mechanism of action is not described, but it is classified within the group of arylpiperazine derivatives known to affect ocular pressure, and it is not currently associated with systemic or other therapeutic indications[1].

Brand names: YCT2-2YCT-2-2YCT 2-2
Other names: YCT2-2YCT-2-2YCT 2-2

Beyond the preview

Go deeper on YCT2-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YCT2-2.

Explore the full profile